We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors.
AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data.
Please refer to your approved national product label SmPC for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. Search Menu. Search Search Search Close. What science can do What science can do Stories of impact Publications.
Careers Great place to work Inclusion and diversity Learning and development Employee resource groups. Sustainability Access to healthcare Overview Access to healthcare Equitable access Affordability and pricing Health system resilience. Overview Ethics and transparency Ethical business culture Inclusion and diversity Workforce safety and health. Sustainability reports and resources Our sustainability impact Sustainable Procurement. Feature Our sustainability impact.
Partnering Our business development teams Our areas of partnering interest Why partner with AstraZeneca? Full Year and Q4 results What science can do. Webcast and investor information. Full Year and Q4 results presentation 4,KB. View announcement. Latest presentations Full Year and Q4 results. View latest results and presentations. We have View pipeline. Learn about our cell therapy ambition.
